Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO(®) (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers

BACKGROUND: HCP1004 is a newly developed fixed-dose combination of naproxen (500 mg) and esomeprazole strontium (20 mg) that is used in the treatment of rheumatic diseases and can reduce the risk of nonsteroidal anti-inflammatory drug-associated ulcers. The aim of this study was to evaluate the phar...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, YoonJung, Han, HyeKyung, Shin, Dongseong, Lim, Kyoung Soo, Yu, Kyung-Sang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4527374/
https://www.ncbi.nlm.nih.gov/pubmed/26257511
http://dx.doi.org/10.2147/DDDT.S86725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4527374/
https://www.ncbi.nlm.nih.gov/pubmed/26257511
http://dx.doi.org/10.2147/DDDT.S86725

Ejemplares similares